NAPSR news: Novartis Maintains Solid Earnings & Revenue for Second Quarter

WASHINGTON - July 23, 2014 - PRLog -- Novartis announced an increase in net sales for all three of its leading businesses. Group net sales increased 2% (+2% cc) to USD 14.6 billion in the second quarter. Growth products contributed USD 4.7 billion or 32% of Group net sales, up 18% (USD) over the prior-year quarter.  A breakdown of the second quarter results is seen below:

Pharmaceuticals net sales reached USD 8.2 billion (+1%, +1% cc) with volume growth of 5 percentage points and a positive price impact of 2 percentage points. Growth products generated approximately USD 3.4 billion growing 15% compared to last year. These products include: Gilenya, Afinitor, Tasigna, Galvus, Lucentis, Xolair, the COPD (chronic obstructive pulmonary disease) portfolio[2] and Jakavi - contributed 42% of division net sales, compared to 36% in the 2013 quarter.

Alcon posted net sales of USD 2.8 billion (+3%, +4% cc) in the second quarter, led by growth in Ophthalmic Pharmaceuticals and Surgical, coupled with strong Emerging Growth Markets performance (+6%, +10% cc).  Surgical Sales grew due to strong device and equipment sales and the launch of Alcon's new Centurionphacoemulsification cataract platform, and the LenSx femtosecond laser system for cataract surgery. Ophthalmic Pharmaceuticals grew (+3%, +4% cc)  and Vision Care grew (+2%, +1% cc) due to solid contact lens sales growth.

Sandoz net sales were USD 2.3 billion in the second quarter, increasing 5%. Asia (excluding Japan) delivered double-digit sales growth (cc), while Central and Eastern Europe and the US grew at a high single-digit rate. Japan displayed double-digit sales growth. German sales of retail generics and biosimilars grew 1%. Sandoz currently holds the leading global position in biosimilars (USD 128 million, +23% cc)

NOW IS THE TIME TO ENTER INTO THIS WONDERFUL FIELD!
With such industry leaders posting gains in profitability, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to market their product both proficiently and efficiently.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!
The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information.